Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells

Oncogene

Volumn 35, Issue 32, 2016, Pages 4235-4243

  Chan, J Y ^a   Lapara, K ^b   Yee, D ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PEPTIDE; PROTEIN KINASE B; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; IGF1R PROTEIN, HUMAN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; S961 PEPTIDE; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER CELL LINE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, INSULIN; RECEPTORS, SOMATOMEDIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84958073795     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.488     Document Type: Article

References (47)

1. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5, 993 breast cancers. Am J Clin Pathol 2005; 123: 21-27.
2. Macaskill EJ, Renshaw L, Dixon JM. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist 2006; 11: 1081-1088.
3. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 4883-4890.
4. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643-658.
5. Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011; 20: S42-S49.
6. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011; 366: 520-529.
7. Garber K. The cancer drug that almost wasn't. Science 2014; 345: 865-867.
8. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 423-429.
9. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M et al. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology 2009; 77: 23-37.
10. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997; 152: 39-47.
11. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011; 25: 516-528.
12. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975-981.
13. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type i insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012; 72: 3372-3380.
14. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 2011; 18: 565-577.
15. Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol 2014; 25: 605-610.
16. Chen HX, Sharon E. IGF-1R as an anti-cancer target-trials and tribulations. Chin J Cancer 2013; 32: 242-252.
17. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. Embo J 1986; 5: 2503-2512.
18. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007; 282: 25649-25658.
19. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67: 391-397.
20. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
21. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992; 52: 3924-3930.
22. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010; 29: 2517-2527.
23. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: R125-R147.
24. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1510.
25. Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 701-711.
26. Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 693-700.
27. Knudsen L, Hansen BF, Jensen P, Pedersen TA, Vestergaard K, Schaffer L et al. Agonism and antagonism at the insulin receptor. PLoS One 2012; 7: e51972.
28. Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, Bellatin J et al. Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem J 1986; 235: 199-208.
29. O'Brien RM, Soos MA, Siddle K. Monoclonal antibodies to the insulin receptor stimulate the intrinsic tyrosine kinase activity by cross-linking receptor molecules. EMBO J 1987; 6: 4003-4010.
30. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat 2009; 114: 277-285.
31. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-221.
32. Josefson D. High insulin levels linked to deaths from breast cancer. BMJ 2000; 320: 1496.
33. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 2007; 28: 763-777.
34. Weinstein D, Sarfstein R, Laron Z, Werner H. Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells. Endocr Connect 2014; 3: 24-35.
35. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010; 107: 10791-10798.
36. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288.
37. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989; 3: 1263-1269.
38. Jones HE, Gee JMW, Barrow D, Tonge D, Holloway B, Nicholson RI. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer 2006; 95: 172-180.
39. Jiang L, Zhu W, Streicher K, Morehouse C, Brohawn P, Ge X et al. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelialmesenchymal transition signature and longer survival in squamous cell lung carcinoma. BMC Cancer 2014; 14: 131.
40. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 2012; 22: 108-115.
41. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 2002; 143: 3259-3267.
42. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586-623.
43. Rostoker R, Abelson S, Bitton-Worms K, Genkin I, Ben-Shmuel S, Dakwar M et al. Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer 2015; 22: 145-157.
44. Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48: R31-R43.
45. Jaques G, Kiefer P, Rotsch M, Hennig C, Goke R, Richter G et al. Production of insulin-like growth factor binding proteins by small-cell lung cancer cell lines. Exp Cell Res 1989; 184: 396-406.
46. Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS et al. Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prev Res (Phila) 2015; 8: 231-239.
47. Ramos RR, Swanson AJ, Bass J. Calreticulin and Hsp90 stabilize the human insulin receptor and promote its mobility in the endoplasmic reticulum. Proc Natl Acad Sci USA 2007; 104: 10470-10475.